siRNAPK/PDSCRare Disease

Givosiran PK Simulator

Indication: Acute Hepatic Porphyria

Interactive PK/PD simulator for givosiran (Givlaari) in acute hepatic porphyria. Explore ALA reduction and dosing optimization.

Drug Overview

Clinical Context

Molecular Target
ALAS1
Drug Class
siRNA
Therapeutic Area
Rare Disease
Indication
Acute Hepatic Porphyria
Route of Administration
SC

Model Information

Model Type
PK/PD

This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.

Pharmacokinetic Parameters

PK Parameters

ParameterValue
ka0.308 h⁻¹
CL F38.8 L/h (70kg)
Vc F26.3 L (70kg)
bioavailability~0.50
protein binding>90%

Additional Parameters

ParameterValue
dose2.5 mg/kg SC monthly
IIV CL44.5% CV
IIV Vc67.2% CV
t half absorption2.25 h
t half elimination~6 h (plasma)

Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.

About This Simulator

This interactive pharmacokinetic simulator for Givosiran allows you to explore concentration-time profiles under different dosing scenarios. The underlying PK/PD model characterizes the pharmacokinetics of this sirna following sc administration.

Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.

Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.

Frequently Asked Questions

What is the Givosiran PK simulator?

This is a free, interactive pharmacokinetic simulator for Givosiran used in Acute Hepatic Porphyria. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.

What drug class does Givosiran belong to?

Givosiran is classified as a siRNA that targets ALAS1. It is used in the Rare Disease therapeutic area.

What route of administration does this model simulate?

This simulator models SC administration of Givosiran. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.

What type of PK model is used?

This simulator uses a PK/PD model. PK/PD models link drug concentrations to pharmacological effects, allowing exploration of exposure-response relationships.

Is this simulator free to use?

Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.

Can I use this for clinical dosing decisions?

No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.

What is the clearance of Givosiran?

The clearance (CL) of Givosiran is approximately 38.8 L/h (70kg). Clearance represents the volume of plasma from which drug is completely removed per unit time and is a key determinant of drug exposure and steady-state concentrations.

Related Simulators

Ready to Simulate?

Launch the Givosiran simulator to explore dosing scenarios and pharmacokinetic profiles interactively.

🚀 Launch Simulator

Comments

0/2000
Loading comments...

⚠️ Disclaimer

This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.

Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community